Abstract
Allogeneic hematopoietic stem cell transplantation is a well-proven treatment for hematologic malignancies and non-malignancies, but it has a high risk of disease recurrence and severe transplant-related morbidity and death. The mortality and long-term survival of post-allogeneic hematopoietic stem cell transplant patients are improving due to improvements in condition procedures, methods, novel medicines, and supportive care practices. Allogeneic hematopoietic stem cell transplant (allo-HCT) findings, nonetheless, still present a chance for recovery. The results of this investigation updated previous research on risk factors for death following allogeneic HCT. We performed a systematic review and meta-analysis to assess mortality post allo-HCT through a comprehensive literature search using PUBMED/MEDLINE, CINAHL, Web of Science, and EMBASE up to April 30, 2023 and extracted clinical outcome data relating to benefits followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search identified 551 studies. Only 12 studies (n = 450 patients) met our inclusion criteria. OS rates were the subject of the meta-analysis. The following were the outcomes of heterogeneity tests: According to Chi2=9.14, df=6, P=0.17, and I2=34 percent, the study's data did not appear to be heterogeneous. The OS rate did not differ significantly (P>0.05) using the fixed-effect model analysis. In conclusion, the HSCT must offer the best overall survival, quality of life, and cost outcomes compared to any other treatment strategy. More studies will need a lot of data, and careful data analysis will help get clear data on HSCT outcomes.
Publisher
BM-Publisher American Journal of BioMedicine
Reference34 articles.
1. Graft failure after allogeneic hematopoietic stem cell transplantation;Ozdemir;Transfus Apher Sci,2018
2. Risk factors for acute GVHD and survival after hematopoietic cell transplantation;Zhang;Blood,2012
3. Risk and prognostic factors for acute GVHD based on NIH consensus criteria;Lee;Bone Marrow Transplant,2013
4. 4. Xue S, Liu F, Zhang Y, Tan Y, Wang J. Clinical study of cord blood mesenchymal stem cells combined with Eltrombopag when treating graft dysfunction after allogeneic hematopoietic stem cell transplantation. Int J Blood Transfus Hematol 2022; 45:132-139.
5. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival;Eapen;Biol Blood Marrow Transplant,2007